Shared HLA-Bound Neoepitopes Are New Targets for Pancreatic Cancer Immunotherapy.

IF 10 1区医学 Q1 ONCOLOGY

Clinical Cancer Research Pub Date : 2025-05-15 DOI:10.1158/1078-0432.CCR-24-4368

Hao Yuan, Qun Chen, Kuirong Jiang, Courtney W Houchen, Yuqing Zhang, Min Li

引用次数: 0

Abstract

The shared HLA-bound neoepitopes in pancreatic ductal adenocarcinoma (PDAC) represent a novel class of noncanonical antigens with single amino acid substitutions resulting from translational errors. These peptides, shared across patients with PDAC, showed higher immunogenicity than wild-type counterparts, offering potential candidates for specific immunotherapy development in PDAC. See related article by Zhang et al., p. 1956.

查看原文本刊更多论文

共享hla结合新表位是胰腺癌免疫治疗的新靶点。

胰腺导管腺癌（PDAC）中共享的hla结合新表位代表了一类由翻译错误导致的单氨基酸取代的新型非规范抗原。这些肽在PDAC患者中共享，显示出比野生型肽更高的免疫原性，为PDAC特异性免疫治疗的发展提供了潜在的候选物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Cancer Research 医学-肿瘤学

CiteScore

20.10

自引率

1.70%

发文量

1207

审稿时长

2.1 months

期刊介绍： Clinical Cancer Research is a journal focusing on groundbreaking research in cancer, specifically in the areas where the laboratory and the clinic intersect. Our primary interest lies in clinical trials that investigate novel treatments, accompanied by research on pharmacology, molecular alterations, and biomarkers that can predict response or resistance to these treatments. Furthermore, we prioritize laboratory and animal studies that explore new drugs and targeted agents with the potential to advance to clinical trials. We also encourage research on targetable mechanisms of cancer development, progression, and metastasis.